JP2008505871A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505871A5
JP2008505871A5 JP2007519812A JP2007519812A JP2008505871A5 JP 2008505871 A5 JP2008505871 A5 JP 2008505871A5 JP 2007519812 A JP2007519812 A JP 2007519812A JP 2007519812 A JP2007519812 A JP 2007519812A JP 2008505871 A5 JP2008505871 A5 JP 2008505871A5
Authority
JP
Japan
Prior art keywords
alkoxy
alkyl
optionally
alk
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007519812A
Other languages
English (en)
Japanese (ja)
Other versions
JP4842262B2 (ja
JP2008505871A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/053306 external-priority patent/WO2006005741A2/en
Publication of JP2008505871A publication Critical patent/JP2008505871A/ja
Publication of JP2008505871A5 publication Critical patent/JP2008505871A5/ja
Application granted granted Critical
Publication of JP4842262B2 publication Critical patent/JP4842262B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007519812A 2004-07-09 2005-07-11 レニン阻害剤としてのピペリジン誘導体 Expired - Fee Related JP4842262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH11582004 2004-07-09
CH1158/04 2004-07-09
PCT/EP2005/053306 WO2006005741A2 (en) 2004-07-09 2005-07-11 Piperdine derivatives as renin inhibitors

Publications (3)

Publication Number Publication Date
JP2008505871A JP2008505871A (ja) 2008-02-28
JP2008505871A5 true JP2008505871A5 (OSRAM) 2008-08-28
JP4842262B2 JP4842262B2 (ja) 2011-12-21

Family

ID=35448323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519812A Expired - Fee Related JP4842262B2 (ja) 2004-07-09 2005-07-11 レニン阻害剤としてのピペリジン誘導体

Country Status (14)

Country Link
US (1) US20080076766A1 (OSRAM)
EP (1) EP1776359B1 (OSRAM)
JP (1) JP4842262B2 (OSRAM)
CN (1) CN101014594A (OSRAM)
AR (1) AR053406A1 (OSRAM)
AT (1) ATE521607T1 (OSRAM)
BR (1) BRPI0513199A (OSRAM)
CA (1) CA2570920A1 (OSRAM)
ES (1) ES2372502T3 (OSRAM)
IL (1) IL180242A0 (OSRAM)
PL (1) PL1776359T3 (OSRAM)
PT (1) PT1776359E (OSRAM)
TW (1) TW200613274A (OSRAM)
WO (1) WO2006005741A2 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510755A (ja) 2004-08-25 2008-04-10 アクテリオン ファーマシューティカルズ リミテッド ビシクロノネン誘導体
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
TW200722424A (en) * 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
BRPI0609534A2 (pt) * 2005-03-31 2010-04-13 Speedel Experimenta Ag piperidinas 3,4,5-substituìdas
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
KR100963455B1 (ko) 2005-05-27 2010-06-18 액테리온 파마슈티칼 리미티드 신규한 피페리딘 카르복실산 아미드 유도체
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2430139T3 (es) 2005-12-30 2013-11-19 Novartis Ag Compuestos de piperidina 3,5-sustituido como inhibidores de renina
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
TW200804359A (en) * 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
EP1911758A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenyl piperidine derivatives for use as renin inhibitors
EP1908761A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds
WO2008074450A2 (en) * 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
EP2181105B1 (en) 2007-06-25 2015-04-29 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
AR069005A1 (es) * 2007-10-25 2009-12-23 Speedel Experimenta Ag Piperidinas 4,4-disustituidas
TW200932241A (en) * 2007-12-05 2009-08-01 Speedel Experimenta Ag Organic compounds
JP2011511038A (ja) 2008-02-08 2011-04-07 ノバルティス アーゲー レニン阻害剤としての置換ピペリジン
EA201001239A1 (ru) 2008-02-08 2011-04-29 Новартис Аг Замещённые пиперидины в качестве ингибиторов ренина
WO2009106599A2 (en) * 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
CN102015682B (zh) * 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物
PE20110067A1 (es) 2008-06-19 2011-02-18 Takeda Pharmaceutical Derivados de piperidina como inhibidores de renina
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
US8592454B2 (en) 2008-09-19 2013-11-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
US20120035214A1 (en) * 2009-04-03 2012-02-09 Merck Canada Inc. Renin inhibitors
EP2384745A3 (en) * 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US8563035B2 (en) 2010-05-05 2013-10-22 Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi Oral tablet compositions of dexlansoprazole
EP4255909A1 (en) * 2020-12-02 2023-10-11 Qurient Co. Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
JP2025510646A (ja) 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100384979B1 (ko) * 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) * 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US20030095958A1 (en) * 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors

Similar Documents

Publication Publication Date Title
JP2008505871A5 (OSRAM)
JP6716785B2 (ja) Hivウイルス感染症の予防的または治療的処置に有用な治療用化合物
AU715380B2 (en) Pyrazolopyrimidines for treatment of neuronal and other disorders
JP2020517618A (ja) Ehmt2阻害剤との併用療法
AU2021200164B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP2018524298A5 (OSRAM)
JP2020011998A (ja) ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2020531434A (ja) Hivカプシド阻害剤の固体形態
CA2782213C (en) 1,7-diazacarbazoles and their use in the treatment of cancer
CN109789143A (zh) 基于嘧啶的抗增殖剂
AR033845A1 (es) Compuestos de aza y poliaza-naftalenil carboxamidas utiles como inhibidores de la integrasa del vih, composiciones y su uso en la preparacion de medicamentos
CA2472372A1 (en) Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
JP2020509040A (ja) 併用療法
EP3848026A1 (en) Combinations and methods comprising a capsid assembly inhibitor
JPWO2023018809A5 (OSRAM)
WO2019246300A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
WO2000069464A1 (en) Novel use
AU2017393082A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2709776A1 (en) Substituted pyrrolo[2, 3-b] and pyrazolo[3, 4-b] pyridines for use as adenosine receptor ligands
WO2021163633A1 (en) Mono and combination therapies with ulk1/2 inhibitors
RU2019108259A (ru) Комбинированная терапия для лечения гепатоцеллюлярной карциномы
MX2013013326A (es) Agente antipruritico.
JP2009517411A5 (OSRAM)
WO2018201006A1 (en) Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors